Transformational cell therapies for patients with pancreatic disease

Ariel Sivikofsky

Ariel Sivikofsky, FCA

Chief Financial Officer

Mr. Sivikofsky has over 20 years’ industry experience in the biotech industry, financial services and accounting both in Australia and Europe. Mr. Sivikofsky is a seasoned finance executive, having been the Chief Financial Officer at Luoda Pharma and Bova UK, private biotech companies based in London, and Investor First Limited (now HUB24 Limited), an ASX-listed financial services company (ASX:INQ (now HUB).

Further, Mr. Sivikofsky previously served as a Director of Financial Advisory Services at Deloitte Australia, where he specialized in Chief Financial Officer secondments and technical accounting advisory engagements. Prior to that role, Mr. Sivikofsky was a financial controller at Babcock & Brown in both Sydney and London. Mr. Sivikofsky is a Chartered Accountant (FCA) and a graduate member of the Australian Institute of Company Directors (GAICD).

Mr. Sivikofsky has a Bachelor of Commerce degree from the University of Wollongong (majoring in Finance & Accounting) and a Graduate Diploma in Applied Finance & Investment from FINSIA.

Kyslecel personalized cell therapy for chronic pancreatitis. Because pain should not define your life.